Cancer interception with KRAS inhibitors in preclinical models of pancreatic ductal adenocarcinoma - PubMed
14 hours ago
- #Pancreatic cancer
- #KRAS inhibitors
- #Cancer interception
- KRAS inhibitors tested in preclinical models of pancreatic ductal adenocarcinoma (PDAC).
- Treatment led to regression of precancerous lesions (PanINs) and delayed tumor onset.
- Long-term interception significantly increased overall survival (OS) in mice.
- Cancer interception with KRAS inhibitors provided greater survival benefit than treatment after cancer onset.
- Findings suggest pharmacological interception can reduce premalignant burden and improve survival in PDAC.